TH69748A - Pituitary adenylate cycls activating peptide (PACAP) completely gripped with receptor 3 (R3) and using ... - Google Patents

Abstract

DC60 (25/12/43) This invention provides a novel peptide whose biological function is to stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner. These insulin-stimulating peptides have been shown to stimulate insulin secretion in mouse islet cells, both in vitro and in vivo. The invention's peptide offers a novel therapeutic approach for patients with reduced intracellular insulin secretion, particularly those with type 2 diabetes. The invention is a polypeptide selected from a group of polypeptides specifically related to VIP/PACAP or their derivatives that perform similar functions. The invention also addresses therapeutic approaches to treating metabolic disorders in mammals by administering the insulin-stimulating peptide in therapeutic doses. The invention also reveals methods for producing this peptide, both via molecular genetic recombination and synthetic methods. This invention provides a novel peptide. In living organisms, its function is to stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner. These insulin-stimulating peptides have been shown to stimulate insulin secretion in mouse islet cells, both in vitro and in vivo. This invention's peptide offers a novel therapeutic approach for patients with reduced intracellular insulin secretion, particularly those with type 2 diabetes. The invention is a polypeptide selected from a group of polypeptides specifically related to VIP/PACAP or its derivatives that perform the same function. The invention also addresses therapeutic approaches for treating metabolic disorders in mammals by administering the insulin-stimulating peptide in therapeutic doses. The invention also reveals methods for producing this peptide, both via molecular biology techniques through gene recombination and through synthetic methods.

Claims (26)

1. Polypeptides selected from groups containing SEQ ID NOs from 11 to 14, SEQ ID NOs from 21 to 26, SEQ ID NOs from 32 to 36, SEQ ID NOs from 40 to 53, SEQ ID NOS from 57 to 61, SEQ ID NOs from 63 to 99, SEQ ID NOs from 102 to 119, SEQ ID NOs from 121 to 137, SEQ ID NOs from 139 to 177, SEQ ID NOs from 179 to 180, SEQ ID NOs from 183 to 202, SEQ ID NOs from 322 to 341, and fragments, derivatives, and altered forms of the normal additive, all possessing similar functional properties. 2. Polynucleotides containing the polypeptide sequence code as per Patent 1, or those that deviate from the standard or normal form of the additive. 3. A DNA vector containing polynucleotides, as per claim 2. 4. Host cells containing the carrier DNA according to Claim 3. 5. The polypeptide production method consists of: a) culturing host cells according to claim 4 under suitable conditions to induce gene expression in the polypeptide; and b) extracting the polypeptide from the cell culture. 6. Pharmaceutical preparations containing the polypeptides as per Patent 1 and a pharmaceutically acceptable carrier. 7. A gene therapy product consisting of the polynucleotides described in Patent 2 and a DNA vector with gene therapy efficacy. 8. Polypeptide according to claim 1, when such polypeptide is represented by SEQ ID NO: 18. 9. Polypeptide according to claim 1, when such polypeptide is represented by SEQ ID NO: 32. 10. Polypeptide according to claim 1, when such polypeptide is represented by SEQ ID NO: 43. 11. Polypeptide according to claim 1, when such polypeptide is represented by SEQ ID NO: 45. 12. Polypeptide according to claim 1, when such polypeptide is represented by SEQ ID NO: 47. 13. Polypeptide according to claim 1, when such polypeptide is represented by SEQ ID NO: 50. 14. Polypeptide according to claim 1, when such polypeptide is represented by SEQ ID NO: 52. 15. Polypeptide according to claim 1, when such polypeptide is represented by SEQ ID NO: 71. 16. Polypeptide according to claim 1, when such polypeptide is represented by SEQ ID NO: 72. 17. Polypeptide according to claim 1, when such polypeptide is represented by SEQ ID NO: 83. 18. Polypeptide according to claim 1, when such polypeptide is represented by SEQ ID NO: 86. 19. Polypeptide according to claim 1, when such polypeptide is represented by SEQ ID NO: 87. 20. Selected peptides from the groups SEQ ID NO: 18, SEQ ID NO: 32, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 83, SEQ ID NO: 86, and SEQ ID NO: 87 were used to prepare pharmaceutical mixtures for therapeutic purposes in treating metabolic disorders. 21. Use under claim 20 when the metabolic disorder is type 2 diabetes. 22. Application under Claim 20: When a metabolic disorder is present, characterized by impaired glucose metabolism, resulting in decreased glucose tolerance. 23. A modified peptide that affects the intestinal blood vessels, with a structure based on one of the structures in Figure 1 and its equivalent functions. 24. Polypeptides, selected from the group of polypeptides shown in Figure 1, were used to prepare a mixture to stimulate glucose-dependent insulin secretion. 25. The use of selected peptides from the groups containing SEQ ID NO: 18, SEQ ID NO: 32, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 83, SEQ ID NO: 86, and SEQ ID NO: 87 for the preparation of pharmaceutical mixtures for the treatment of asthma. 26. A purified antibody that specifically binds to the polypeptide described in Claim 1.